

# Victor Sapena

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9278531/publications.pdf>

Version: 2024-02-01

32  
papers

475  
citations

933447

10  
h-index

713466

21  
g-index

33  
all docs

33  
docs citations

33  
times ranked

743  
citing authors

#	ARTICLE	IF	CITATIONS
1	Incidence of Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-analysis, and Meta-regression. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 283-292.e10.	4.4	94
2	Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules. <i>Journal of Hepatology</i> , 2019, 70, 874-884.	3.7	67
3	Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. <i>Cut</i> , 2022, 71, 593-604.	12.1	62
4	Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 482-491.	3.7	40
5	Assessing the impact of COVID-19 on liver cancer management (CERO-19). <i>JHEP Reports</i> , 2021, 3, 100260.	4.9	36
6	Validation of the Simplified Magnetic Resonance Index of Activity [sMARIA] Without Gadolinium-enhanced Sequences for Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1074-1081.	1.3	26
7	Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma. <i>European Radiology</i> , 2020, 30, 186-194.	4.5	25
8	Radiological response to nivolumab in patients with hepatocellular carcinoma: A multicenter analysis of real-life practice. <i>European Journal of Radiology</i> , 2021, 135, 109484.	2.6	20
9	Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules. <i>Journal of Hepatology</i> , 2022, 76, 874-882.	3.7	17
10	Hepatic epithelioid hemangioendothelioma: An international multicenter study. <i>Digestive and Liver Disease</i> , 2020, 52, 1041-1046.	0.9	13
11	Avoiding contrast-enhanced sequences does not compromise the precision of the simplified MaRIA for the assessment of non-penetrating Crohn's disease activity. <i>European Radiology</i> , 2022, 32, 3334-3345.	4.5	11
12	Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study. <i>Liver International</i> , 2022, 42, 1891-1901.	3.9	11
13	Anti-miR-518d-5p overcomes liver tumor cell death resistance through mitochondrial activity. <i>Cell Death and Disease</i> , 2021, 12, 555.	6.3	10
14	Limited tumour progression beyond Milan criteria while on the waiting list does not result in unacceptable impairment of survival. <i>Journal of Hepatology</i> , 2021, 75, 1154-1163.	3.7	9
15	Does transient arterial-phase respiratory-motion-related artifact impact on diagnostic performance? An intra-patient comparison of extracellular gadolinium versus gadoxetic acid. <i>European Radiology</i> , 2020, 30, 6694-6701.	4.5	8
16	Pharmacokinetics and pharmacogenetics of sorafenib in patients with hepatocellular carcinoma: Implications for combination trials. <i>Liver International</i> , 2020, 40, 2476-2488.	3.9	6
17	Towards personalised approach in systemic treatment for hepatocellular carcinoma. The value of AGT M235T gene polymorphism. <i>Journal of Hepatology</i> , 2018, 68, S197.	3.7	4
18	Activated Lymphocytes and Increased Risk of Dermatologic Adverse Events during Sorafenib Therapy for Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 426.	3.7	4

#	ARTICLE	IF	CITATIONS
19	Missing colorectal liver metastases: the surgical challenge. <i>Langenbeck's Archives of Surgery</i> , 2021, 406, 2163-2175.	1.9	3
20	Pancreatic Insufficiency in Patients Under Sorafenib Treatment for Hepatocellular Carcinoma. <i>Journal of Clinical Gastroenterology</i> , 2021, 55, 263-270.	2.2	3
21	EarlyÂdiarrhoea under sorafenib as a marker to consider the early migration to secondâ€line drugs. <i>United European Gastroenterology Journal</i> , 2021, 9, 655-661.	3.8	2
22	Impact of regorafenib in the clinical practice and identification of second-line treatment orphan patients. <i>Journal of Hepatology</i> , 2018, 68, S205-S206.	3.7	1
23	Reply to: â€œThe reported â€clear cut time association between interferon-free treatment and HCCâ€™™ is anything but clear cutâ€•. <i>Journal of Hepatology</i> , 2020, 72, 1036-1037.	3.7	1
24	Mutational profile of skin lesions in hepatocellular carcinoma patients under tyrosine kinase inhibition: a repercussion of a wide-spectrum activity. <i>Oncotarget</i> , 2021, 12, 440-449.	1.8	1
25	Clinicopathological evaluation of skin lesions (SL) in patients with hepatocellular carcinoma (HCC) treated with sorafenib. <i>Annals of Oncology</i> , 2018, 29, viii238.	1.2	0
26	Increased risk of liver cancer in cirrhotic patients associated to direct acting antivirals. <i>Journal of Hepatology</i> , 2018, 68, S118.	3.7	0
27	Transarterial-chemoembolization and hepatocellular carcinoma. A regular interval approach avoids the 10% of the procedures and an optimal survival with the transition to systemic therapy in 80% of the patients. <i>Journal of Hepatology</i> , 2018, 68, S205.	3.7	0
28	Systematic review and metanalysis establish dermatologic adverse events as a positive predictor of survival in hepatocellular carcinoma patients treated with sorafenib. <i>Journal of Hepatology</i> , 2018, 68, S195.	3.7	0
29	FRI-417-Impact of a nurse educational program and accessibility in the management of patients with hepatocellular carcinoma under systemic treatment. <i>Journal of Hepatology</i> , 2019, 70, e577-e578.	3.7	0
30	Reply to: â€œTime association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules â€“ A responseâ€•. <i>Journal of Hepatology</i> , 2019, 71, 447-448.	3.7	0
31	Letter: are sorafenibâ€™related adverse events associated with prolonged survival? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 192-192.	3.7	0
32	Low Baseline Plasma L-Glutamine Concentration Identifies Hepatocellular Carcinoma Patients at High Risk of Developing Early Gastrointestinal Adverse Events during Sorafenib Treatment. <i>Gastrointestinal Disorders</i> , 2022, 4, 141-152.	0.8	0